Optimum Profesorskie Centrum Okulistyki Sp. z o.o.
- Address
- Ul. Cienista 30, 80-809 Gdansk, Poland
Optimum Profesorskie Centrum Okulistyki - Advanced Ophthalmology Research Center
Optimum Profesorskie Centrum Okulistyki is a specialized ophthalmology research center dedicated to advancing treatments for sight-threatening retinal and glaucomatous conditions. The center focuses on innovative therapeutic approaches, including novel drug delivery systems and optimized dosing regimens for complex ocular diseases that significantly impact patient quality of life.
- Open-angle glaucoma and ocular hypertension management with sustained-release drug delivery systems
- Retinal vein occlusion complications including macular edema treatment optimization
- Intravitreal anti-VEGF therapy development and dosing interval evaluation
The center's research portfolio emphasizes intraocular pressure (IOP) control through innovative bimatoprost sustained-release implants for patients who cannot adequately use topical medications, as well as investigations into higher-dose aflibercept formulations for macular edema secondary to retinal vein occlusion. This work addresses critical unmet needs in patient adherence and treatment burden reduction in chronic ophthalmologic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Optimum Profesorskie Centrum Okulistyki Sp. z o.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 1 | Unknown | 2023-09-13 | 2023-09-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.